Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials. - Wikidata - awgldk - TriplyDB

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

http://www.wikidata.org/entity/Q37904800

about

Taxanes in the Treatment of Advanced Gastric Cancer Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.

P2860

Q26747708-9278B535-C5E4-496C-937E-35C26700A3E6 Q33419166-555BDB4F-E6E9-4956-8FBB-CCE4E4DCF16E Q36275405-A637B784-B145-4151-8049-C97DCD7DEC5A Q44923328-C43B5599-65A6-4BC3-AB94-BD4BF80B3AAF

P2860

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

http://www.wikidata.org/entity/Q37904800

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@en

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@nl

type

label

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@en

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@nl

prefLabel

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@en

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@nl

P1433

Q37904800-155FC7F4-DE15-4A28-9E92-2E4480610EE2

P1476

Q37904800-7F9959C1-550C-40BF-9FDA-0D5A422B5E1B

P2093

Q37904800-8F18C22B-FEE9-4187-A6AF-A339EB36C808

P2860

Q37904800-0BA803FB-3191-4A4A-8051-914C3120D0E2

Q37904800-1BB2EF99-DBF6-4A65-840B-D8E4E7B6CDCE

Q37904800-1F3F368C-B641-4161-B593-9236A597934A

Q37904800-2F9A9397-1B1B-4B1A-8D09-6CB5C2457E02

Q37904800-381493AE-BD53-49B2-9B56-207A4C26A386

Q37904800-3ACCBD32-E262-4BDF-96EB-EC4F9C35A58E

Q37904800-3C5011C0-ED5D-4EEC-A07E-E7CFE29CCF93

Q37904800-45035C4B-EC67-49DB-905D-B47F2290EEBC

Q37904800-4B4A9508-D7BE-488B-9034-3FB9ADB1E094

Q37904800-58525226-4032-4A84-803E-2CD1B1388124

P2888

Q37904800-97DC4C31-B8A5-4227-8840-A1E83C81FAE5

P304

Q37904800-5F0918C7-506E-4CF1-BB6E-C6EC22F65888

P31

Q37904800-19AD3550-934B-4994-BEF4-CE13F9E8E3E3

P356

Q37904800-806B2682-0483-4A21-8A18-DA027F065E35

P433

Q37904800-FE1A31F9-926F-4F05-BBB2-2D1DA3243031

P478

Q37904800-40CE16D2-38C5-449C-811A-99C3C0709CE6

P577

Q37904800-C784F661-5673-4D77-932A-5392EBAA6317

P5875

Q37904800-80A15AD1-8E16-4A1D-B453-F3418121A150

P698

Q37904800-EDDFBD5E-8670-4579-BB26-CA5DB1876797

P921

Q37904800-D307AAEC-C5BE-4685-8A2E-DCBBCC561ECA

P356

S10120-011-0072-Y

P1433

P1476

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials.

@en

P2093

Hiroya Takiuchi

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2006

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

P2888

s10120-011-0072-y

P304

206-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-011-0072-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51518205

http://www.w3.org/2001/XMLSchema#string

P698

21785927

http://www.w3.org/2001/XMLSchema#string

P921